Swiss guests visit Cell Valley in Shenzhen to discuss deepening technology and industry integration on the 75th anniversary of China-Switzerland diplomatic relations
Recently, Mr. Yunlong Song, member of the Swiss Federal Ministry of Culture, Ms. Li Ying, leader of the 75th Anniversary of China-Switzerland Diplomatic Relations Summit Forum, Mr. Hans Strub, advisor of the Forum, and Mr. Chen Sihan, sponsor of the Forum, visited Shenzhen Cell Valley to carry out in-depth exchanges and cooperation discussions. Professor Shi Yuanyuan, Chairman of our company, Fu Yuchen, assistant chairman of the company, and Sun Rui, director of the Marketing Department, warmly received them, and the two sides held discussions on topics such as cell therapy technology innovation and international industrial cooperation.
Accompanied by Fu Yuchen, assistant to the chairman of the board, the visiting guests first visited the Shenzhen Cell Valley Wisdom exhibition Hall and systematically understood the company's whole industry chain layout in the field of cell and gene therapy. As the only CRO/CDMO service provider with clinical grade retroviral vector (RVV) GMP industrial production capacity in China, Shenzhen Cell Valley has built a viral vector and cell product production line of more than 10,000 square meters in line with international GMP standards, with a single batch of RVV production capacity exceeding 1,000 people, and CAR T cell transducation efficiency of more than 70%.
At the symposium, Professor Shi Yuanyuan, chairman of the board, first expressed a warm welcome to the guests. He stressed that Shenzhen Cell Valley has always taken "cells benefit all sentient beings and genes create the future" as its mission. The company not only cooperates with the Cell Therapy Transformation Research Institute of Shenzhen Hospital of Southern Medical University, but also deeply cooperates with the National Engineering Research Center of Key common technologies of the cell industry and other institutions to create a full-cycle service platform from carrier design to clinical declaration. Facing the future, Shenzhen Cell Valley will rely on the opportunity of the Summit Cooperation Forum on the 75th anniversary of the establishment of diplomatic relations between China and Switzerland, and look forward to exchanges and cooperation with Switzerland in the field of medicine and medicine.
Hans Strub said that cell therapy, as a strategic highland in the field of biomedicine, is in urgent need of cross-border resource integration and technology iteration. Mr. Yunlong Song, member of the Swiss Federal Ministry of Culture, also said that he would like to take this visit as an opportunity to build a bridge of cooperation between China and Switzerland in the cell therapy industry and help the innovation achievements of the two countries in the field of life sciences to benefit patients around the world.
Professor Shi Yuanyuan said that Shenzhen Cell Valley is committed to promoting international scientific and cultural exchanges and cooperation, and hopes to further enhance the international level of cell therapy technology through cooperation with the Swiss medical community. This exchange is an important action for Shenzhen Cell Valley to implement its internationalization strategy. In the future, the company will continue to work with global partners to expand the new boundaries of cell technology with an open and innovative attitude, and contribute Chinese wisdom and Shenzhen strength to the cause of human health.
